Concurrent therapy with immune-DASH inhibitors and PGE2 antagonists

摘要

Concurrent therapy including administration of an I-DASH inhibitor and a PGE2 antagonist, and the use of such therapy in the treatment of a cell proliferative disorder, is disclosed.